PDF(Pubmed)
Abstract：
UNASSIGNED: The treatment outcomes and prognosis for recurrent cervical cancer are generally poor, with a 5-year survival rate of only 10%-20%.
UNASSIGNED: In this case, the patient is a young woman who experienced a recurrence 5 years after the initial treatment of cervical cancer. Her primary symptoms were hemoptysis and dysphagia, indicative of hilar and mediastinal lymph node metastases, with further involvement of the bronchus and esophagus. Additionally, the patient also presented with tumor-associated dermatomyositis. Following combined treatment with albumin-bound paclitaxel, carboplatin, bevacizumab, and cadonilimab, the patient\'s tumor was effectively controlled.
UNASSIGNED: In this case, the patient is a young woman who experienced a recurrence 5 years after the initial treatment of cervical cancer. Her primary symptoms were hemoptysis and dysphagia, indicative of hilar and mediastinal lymph node metastases, with further involvement of the bronchus and esophagus. Additionally, the patient also presented with tumor-associated dermatomyositis. Following combined treatment with albumin-bound paclitaxel, carboplatin, bevacizumab, and cadonilimab, the patient\'s tumor was effectively controlled.
摘要：
■复发性宫颈癌的治疗结果和预后普遍较差，5年生存率仅为10%-20%。
■在这种情况下，患者是一名年轻女性，在最初治疗宫颈癌5年后复发。她的主要症状是咯血和吞咽困难，指示肺门和纵隔淋巴结转移，进一步累及支气管和食道。此外,患者还出现了肿瘤相关性皮肌炎.白蛋白结合型紫杉醇联合治疗后，卡铂,贝伐单抗,还有Cadonilimab,患者的肿瘤得到有效控制。
■在这种情况下，患者是一名年轻女性，在最初治疗宫颈癌5年后复发。她的主要症状是咯血和吞咽困难，指示肺门和纵隔淋巴结转移，进一步累及支气管和食道。此外,患者还出现了肿瘤相关性皮肌炎.白蛋白结合型紫杉醇联合治疗后，卡铂,贝伐单抗,还有Cadonilimab,患者的肿瘤得到有效控制。
